FDA Approves AstraZeneca's Saphnelo Pen for Self-Administration in Lupus Patients
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's Saphnelo (anifrolumab) for self-administration as a once-weekly autoinjector, known as the Saphnelo Pen, for adult patients with systemic lupus erythematosus (SLE). This approval is based on the results from the Phase III TULIP-SC trial, which demonstrated a significant reduction in disease activity for patients with moderate to severe SLE. The trial results, published in Arthritis & Rheumatology, showed that the subcutaneous administration of Saphnelo was both statistically significant and clinically meaningful compared to a placebo. The safety profile of the autoinjector was consistent with the known clinical profile of Saphnelo when administered intravenously. This development is seen as a major advancement in the treatment of lupus, offering patients a more convenient and accessible option. 
